Generation Bio Co.

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, VRTX has a market cap of 112.6B. Regarding current trading prices, GBIO is priced at $5.34, while VRTX trades at $443.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas VRTX's P/E ratio is 28.91. In terms of profitability, GBIO's ROE is -0.95%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, GBIO is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check VRTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, REGN has a market cap of 77.9B. Regarding current trading prices, GBIO is priced at $5.34, while REGN trades at $749.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas REGN's P/E ratio is 18.07. In terms of profitability, GBIO's ROE is -0.95%, compared to REGN's ROE of +0.15%. Regarding short-term risk, GBIO is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check REGN's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, GBIO is priced at $5.34, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas VRNA's P/E ratio is -102.80. In terms of profitability, GBIO's ROE is -0.95%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, GBIO and VRNA have similar daily volatility (0.00).Check VRNA's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ARGX has a market cap of 43.6B. Regarding current trading prices, GBIO is priced at $5.34, while ARGX trades at $704.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ARGX's P/E ratio is 35.99. In terms of profitability, GBIO's ROE is -0.95%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, GBIO is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ARGX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GBIO is priced at $5.34, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GBIO's ROE is -0.95%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GBIO is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check SGEN's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ALNY has a market cap of 41.9B. Regarding current trading prices, GBIO is priced at $5.34, while ALNY trades at $316.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ALNY's P/E ratio is 136.25. In terms of profitability, GBIO's ROE is -0.95%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, GBIO is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ALNY's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, INSM has a market cap of 33B. Regarding current trading prices, GBIO is priced at $5.34, while INSM trades at $153.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas INSM's P/E ratio is -23.84. In terms of profitability, GBIO's ROE is -0.95%, compared to INSM's ROE of -1.68%. Regarding short-term risk, GBIO is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check INSM's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, UTHR has a market cap of 25.8B. Regarding current trading prices, GBIO is priced at $5.34, while UTHR trades at $588.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas UTHR's P/E ratio is 21.11. In terms of profitability, GBIO's ROE is -0.95%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, GBIO is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check UTHR's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, BNTX has a market cap of 21.4B. Regarding current trading prices, GBIO is priced at $5.34, while BNTX trades at $85.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas BNTX's P/E ratio is -15.70. In terms of profitability, GBIO's ROE is -0.95%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, GBIO is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check BNTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GBIO is priced at $5.34, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GBIO's ROE is -0.95%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, GBIO is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check BGNE's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, RPRX has a market cap of 19.9B. Regarding current trading prices, GBIO is priced at $5.34, while RPRX trades at $46.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas RPRX's P/E ratio is 26.05. In terms of profitability, GBIO's ROE is -0.95%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, GBIO is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check RPRX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, MRNA has a market cap of 19B. Regarding current trading prices, GBIO is priced at $5.34, while MRNA trades at $48.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas MRNA's P/E ratio is -6.64. In terms of profitability, GBIO's ROE is -0.95%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, GBIO is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check MRNA's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ROIV has a market cap of 18.9B. Regarding current trading prices, GBIO is priced at $5.34, while ROIV trades at $26.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ROIV's P/E ratio is -22.57. In terms of profitability, GBIO's ROE is -0.95%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, GBIO is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ROIV's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GBIO is priced at $5.34, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GBIO's ROE is -0.95%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, GBIO is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check DNA-WT's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, RVMD has a market cap of 18.4B. Regarding current trading prices, GBIO is priced at $5.34, while RVMD trades at $92.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas RVMD's P/E ratio is -15.58. In terms of profitability, GBIO's ROE is -0.95%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, GBIO is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check RVMD's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, INCY has a market cap of 18B. Regarding current trading prices, GBIO is priced at $5.34, while INCY trades at $90.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas INCY's P/E ratio is 14.09. In terms of profitability, GBIO's ROE is -0.95%, compared to INCY's ROE of +0.29%. Regarding short-term risk, GBIO is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check INCY's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, GMAB has a market cap of 15.9B. Regarding current trading prices, GBIO is priced at $5.34, while GMAB trades at $25.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas GMAB's P/E ratio is 16.77. In terms of profitability, GBIO's ROE is -0.95%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, GBIO is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check GMAB's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, GBIO is priced at $5.34, while BBIO trades at $69.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas BBIO's P/E ratio is -18.35. In terms of profitability, GBIO's ROE is -0.95%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, GBIO is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check BBIO's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ASND has a market cap of 13.4B. Regarding current trading prices, GBIO is priced at $5.34, while ASND trades at $218.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ASND's P/E ratio is -50.31. In terms of profitability, GBIO's ROE is -0.95%, compared to ASND's ROE of +1.28%. Regarding short-term risk, GBIO is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ASND's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, SMMT has a market cap of 12.6B. Regarding current trading prices, GBIO is priced at $5.34, while SMMT trades at $16.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas SMMT's P/E ratio is -11.79. In terms of profitability, GBIO's ROE is -0.95%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, GBIO is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check SMMT's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GBIO is priced at $5.34, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GBIO's ROE is -0.95%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GBIO is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check KRTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, IONS has a market cap of 12B. Regarding current trading prices, GBIO is priced at $5.34, while IONS trades at $72.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas IONS's P/E ratio is -30.47. In terms of profitability, GBIO's ROE is -0.95%, compared to IONS's ROE of -0.69%. Regarding short-term risk, GBIO is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check IONS's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, MDGL has a market cap of 11.6B. Regarding current trading prices, GBIO is priced at $5.34, while MDGL trades at $505.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas MDGL's P/E ratio is -39.26. In terms of profitability, GBIO's ROE is -0.95%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, GBIO is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check MDGL's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, JAZZ has a market cap of 11.3B. Regarding current trading prices, GBIO is priced at $5.34, while JAZZ trades at $183.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas JAZZ's P/E ratio is -31.36. In terms of profitability, GBIO's ROE is -0.95%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, GBIO is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check JAZZ's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, GBIO is priced at $5.34, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas RNAM's P/E ratio is -17.39. In terms of profitability, GBIO's ROE is -0.95%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, GBIO and RNAM have similar daily volatility (0.00).Check RNAM's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, EXEL has a market cap of 11.2B. Regarding current trading prices, GBIO is priced at $5.34, while EXEL trades at $41.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas EXEL's P/E ratio is 15.09. In terms of profitability, GBIO's ROE is -0.95%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, GBIO is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check EXEL's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, BMRN has a market cap of 10.5B. Regarding current trading prices, GBIO is priced at $5.34, while BMRN trades at $54.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas BMRN's P/E ratio is 30.44. In terms of profitability, GBIO's ROE is -0.95%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, GBIO is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check BMRN's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GBIO is priced at $5.34, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GBIO's ROE is -0.95%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GBIO is less volatile compared to RXDX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check RXDX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GBIO is priced at $5.34, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GBIO's ROE is -0.95%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, GBIO is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check IMGN's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GBIO is priced at $5.34, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GBIO's ROE is -0.95%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, GBIO and BPMC have similar daily volatility (0.00).Check BPMC's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, AXSM has a market cap of 8.2B. Regarding current trading prices, GBIO is priced at $5.34, while AXSM trades at $160.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas AXSM's P/E ratio is -43.73. In terms of profitability, GBIO's ROE is -0.95%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, GBIO is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check AXSM's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GBIO is priced at $5.34, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CERE's P/E ratio is -16.47. In terms of profitability, GBIO's ROE is -0.95%, compared to CERE's ROE of -0.72%. Regarding short-term risk, GBIO is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CERE's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, GBIO is priced at $5.34, while TECH trades at $52.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas TECH's P/E ratio is 98.19. In terms of profitability, GBIO's ROE is -0.95%, compared to TECH's ROE of +0.04%. Regarding short-term risk, GBIO is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check TECH's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ARWR has a market cap of 8.1B. Regarding current trading prices, GBIO is priced at $5.34, while ARWR trades at $57.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ARWR's P/E ratio is 36.03. In terms of profitability, GBIO's ROE is -0.95%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, GBIO is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ARWR's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, GBIO is priced at $5.34, while PCVX trades at $54.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas PCVX's P/E ratio is -9.76. In terms of profitability, GBIO's ROE is -0.95%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, GBIO is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check PCVX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, GBIO is priced at $5.34, while CYTK trades at $62.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CYTK's P/E ratio is -9.63. In terms of profitability, GBIO's ROE is -0.95%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, GBIO is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CYTK's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, GBIO is priced at $5.34, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas MTSR's P/E ratio is -23.58. In terms of profitability, GBIO's ROE is -0.95%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, GBIO is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check MTSR's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, HALO has a market cap of 7.3B. Regarding current trading prices, GBIO is priced at $5.34, while HALO trades at $62.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas HALO's P/E ratio is 24.27. In terms of profitability, GBIO's ROE is -0.95%, compared to HALO's ROE of +0.93%. Regarding short-term risk, GBIO is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check HALO's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, KRYS has a market cap of 7.2B. Regarding current trading prices, GBIO is priced at $5.34, while KRYS trades at $246.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas KRYS's P/E ratio is 36.05. In terms of profitability, GBIO's ROE is -0.95%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, GBIO is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check KRYS's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, NUVL has a market cap of 7.1B. Regarding current trading prices, GBIO is priced at $5.34, while NUVL trades at $96.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas NUVL's P/E ratio is -16.53. In terms of profitability, GBIO's ROE is -0.95%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, GBIO is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check NUVL's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, IBRX has a market cap of 6.8B. Regarding current trading prices, GBIO is priced at $5.34, while IBRX trades at $6.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas IBRX's P/E ratio is -17.53. In terms of profitability, GBIO's ROE is -0.95%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, GBIO is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check IBRX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, GBIO is priced at $5.34, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas MRUS's P/E ratio is -17.05. In terms of profitability, GBIO's ROE is -0.95%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, GBIO and MRUS have similar daily volatility (0.00).Check MRUS's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, GBIO is priced at $5.34, while ACLX trades at $114.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ACLX's P/E ratio is -28.20. In terms of profitability, GBIO's ROE is -0.95%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, GBIO is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ACLX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, GBIO is priced at $5.34, while ABVX trades at $101.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ABVX's P/E ratio is -18.19. In terms of profitability, GBIO's ROE is -0.95%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, GBIO is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ABVX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GBIO is priced at $5.34, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas RETA's P/E ratio is -66.29. In terms of profitability, GBIO's ROE is -0.95%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GBIO is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check RETA's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, GBIO is priced at $5.34, while KYMR trades at $79.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas KYMR's P/E ratio is -21.54. In terms of profitability, GBIO's ROE is -0.95%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, GBIO is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check KYMR's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, GBIO is priced at $5.34, while PTGX trades at $99.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas PTGX's P/E ratio is -48.72. In terms of profitability, GBIO's ROE is -0.95%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, GBIO is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check PTGX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, GBIO is priced at $5.34, while BLTE trades at $149.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas BLTE's P/E ratio is -64.30. In terms of profitability, GBIO's ROE is -0.95%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, GBIO is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check BLTE's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, PRAX has a market cap of 5.8B. Regarding current trading prices, GBIO is priced at $5.34, while PRAX trades at $276.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas PRAX's P/E ratio is -20.51. In terms of profitability, GBIO's ROE is -0.95%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, GBIO is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check PRAX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, GBIO is priced at $5.34, while COGT trades at $35.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas COGT's P/E ratio is -16.38. In terms of profitability, GBIO's ROE is -0.95%, compared to COGT's ROE of -1.00%. Regarding short-term risk, GBIO is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check COGT's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, GBIO is priced at $5.34, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CDTX's P/E ratio is -19.77. In terms of profitability, GBIO's ROE is -0.95%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, GBIO and CDTX have similar daily volatility (0.00).Check CDTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GBIO is priced at $5.34, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GBIO's ROE is -0.95%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GBIO is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ABCM's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GBIO is priced at $5.34, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GBIO's ROE is -0.95%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GBIO is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ISEE's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, GBIO is priced at $5.34, while PTCT trades at $65.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas PTCT's P/E ratio is 7.65. In terms of profitability, GBIO's ROE is -0.95%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, GBIO is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check PTCT's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, GBIO is priced at $5.34, while CGON trades at $63.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CGON's P/E ratio is -30.75. In terms of profitability, GBIO's ROE is -0.95%, compared to CGON's ROE of -0.23%. Regarding short-term risk, GBIO is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CGON's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, GBIO is priced at $5.34, while FBIOX trades at $24.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas FBIOX's P/E ratio is N/A. In terms of profitability, GBIO's ROE is -0.95%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, GBIO and FBIOX have similar daily volatility (0.00).Check FBIOX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, RYTM has a market cap of 5.3B. Regarding current trading prices, GBIO is priced at $5.34, while RYTM trades at $77.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas RYTM's P/E ratio is -24.84. In terms of profitability, GBIO's ROE is -0.95%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, GBIO is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check RYTM's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CELC has a market cap of 5.2B. Regarding current trading prices, GBIO is priced at $5.34, while CELC trades at $108.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CELC's P/E ratio is -28.57. In terms of profitability, GBIO's ROE is -0.95%, compared to CELC's ROE of -2.03%. Regarding short-term risk, GBIO is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CELC's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, TGTX has a market cap of 5B. Regarding current trading prices, GBIO is priced at $5.34, while TGTX trades at $31.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas TGTX's P/E ratio is 11.38. In terms of profitability, GBIO's ROE is -0.95%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, GBIO is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check TGTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, GBIO is priced at $5.34, while ALKS trades at $30.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ALKS's P/E ratio is 21.08. In terms of profitability, GBIO's ROE is -0.95%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, GBIO is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ALKS's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, SRRK has a market cap of 4.9B. Regarding current trading prices, GBIO is priced at $5.34, while SRRK trades at $43.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas SRRK's P/E ratio is -13.09. In terms of profitability, GBIO's ROE is -0.95%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, GBIO is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check SRRK's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, IMVT has a market cap of 4.8B. Regarding current trading prices, GBIO is priced at $5.34, while IMVT trades at $23.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas IMVT's P/E ratio is -8.82. In terms of profitability, GBIO's ROE is -0.95%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, GBIO is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check IMVT's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, GBIO is priced at $5.34, while TERN trades at $52.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas TERN's P/E ratio is -51.84. In terms of profitability, GBIO's ROE is -0.95%, compared to TERN's ROE of -0.30%. Regarding short-term risk, GBIO is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check TERN's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CAI has a market cap of 4.8B. Regarding current trading prices, GBIO is priced at $5.34, while CAI trades at $16.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CAI's P/E ratio is -5.23. In terms of profitability, GBIO's ROE is -0.95%, compared to CAI's ROE of +0.25%. Regarding short-term risk, GBIO is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CAI's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ERAS has a market cap of 4.6B. Regarding current trading prices, GBIO is priced at $5.34, while ERAS trades at $14.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ERAS's P/E ratio is -33.95. In terms of profitability, GBIO's ROE is -0.95%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, GBIO is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ERAS's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, GBIO is priced at $5.34, while FOLD trades at $14.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas FOLD's P/E ratio is -160.33. In terms of profitability, GBIO's ROE is -0.95%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, GBIO is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check FOLD's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, GBIO is priced at $5.34, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas AKRO's P/E ratio is -14.57. In terms of profitability, GBIO's ROE is -0.95%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, GBIO is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check AKRO's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GBIO is priced at $5.34, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GBIO's ROE is -0.95%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, GBIO is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ALPN's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, MIRM has a market cap of 4.4B. Regarding current trading prices, GBIO is priced at $5.34, while MIRM trades at $87.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas MIRM's P/E ratio is -187.02. In terms of profitability, GBIO's ROE is -0.95%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, GBIO is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check MIRM's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, APGE has a market cap of 4.4B. Regarding current trading prices, GBIO is priced at $5.34, while APGE trades at $78.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas APGE's P/E ratio is -18.65. In terms of profitability, GBIO's ROE is -0.95%, compared to APGE's ROE of -0.37%. Regarding short-term risk, GBIO is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check APGE's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, GBIO is priced at $5.34, while XENE trades at $55.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas XENE's P/E ratio is -12.74. In terms of profitability, GBIO's ROE is -0.95%, compared to XENE's ROE of -0.56%. Regarding short-term risk, GBIO is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check XENE's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CRSP has a market cap of 4.3B. Regarding current trading prices, GBIO is priced at $5.34, while CRSP trades at $44.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CRSP's P/E ratio is -6.85. In terms of profitability, GBIO's ROE is -0.95%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, GBIO is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CRSP's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GBIO is priced at $5.34, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas OPT's P/E ratio is -1.52. In terms of profitability, GBIO's ROE is -0.95%, compared to OPT's ROE of +0.88%. Regarding short-term risk, GBIO and OPT have similar daily volatility (0.00).Check OPT's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GBIO is priced at $5.34, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GBIO's ROE is -0.95%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GBIO is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check MRTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CORT has a market cap of 4.1B. Regarding current trading prices, GBIO is priced at $5.34, while CORT trades at $38.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CORT's P/E ratio is 46.49. In terms of profitability, GBIO's ROE is -0.95%, compared to CORT's ROE of +0.15%. Regarding short-term risk, GBIO is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CORT's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, LGND has a market cap of 3.8B. Regarding current trading prices, GBIO is priced at $5.34, while LGND trades at $192.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas LGND's P/E ratio is 31.37. In terms of profitability, GBIO's ROE is -0.95%, compared to LGND's ROE of +0.14%. Regarding short-term risk, GBIO is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check LGND's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GBIO is priced at $5.34, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GBIO's ROE is -0.95%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GBIO is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check RYZB's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GBIO is priced at $5.34, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GBIO's ROE is -0.95%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GBIO is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CBAY's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CNTA has a market cap of 3.7B. Regarding current trading prices, GBIO is priced at $5.34, while CNTA trades at $27.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CNTA's P/E ratio is -14.59. In terms of profitability, GBIO's ROE is -0.95%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, GBIO is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CNTA's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, GBIO is priced at $5.34, while ACAD trades at $21.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas ACAD's P/E ratio is 9.16. In terms of profitability, GBIO's ROE is -0.95%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, GBIO is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check ACAD's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, GBIO is priced at $5.34, while CRNX trades at $34.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CRNX's P/E ratio is -6.92. In terms of profitability, GBIO's ROE is -0.95%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, GBIO is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CRNX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, GBIO is priced at $5.34, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas SWTX's P/E ratio is -13.78. In terms of profitability, GBIO's ROE is -0.95%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, GBIO and SWTX have similar daily volatility (0.00).Check SWTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, GBIO is priced at $5.34, while VKTX trades at $29.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas VKTX's P/E ratio is -9.38. In terms of profitability, GBIO's ROE is -0.95%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, GBIO is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check VKTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, GBIO is priced at $5.34, while KNSA trades at $45.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas KNSA's P/E ratio is 60.93. In terms of profitability, GBIO's ROE is -0.95%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, GBIO is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check KNSA's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, NAMS has a market cap of 3.4B. Regarding current trading prices, GBIO is priced at $5.34, while NAMS trades at $29.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas NAMS's P/E ratio is -17.05. In terms of profitability, GBIO's ROE is -0.95%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, GBIO is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check NAMS's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, EWTX has a market cap of 3.2B. Regarding current trading prices, GBIO is priced at $5.34, while EWTX trades at $30.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas EWTX's P/E ratio is -18.58. In terms of profitability, GBIO's ROE is -0.95%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, GBIO is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check EWTX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, GBIO is priced at $5.34, while LEGN trades at $17.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas LEGN's P/E ratio is -10.69. In terms of profitability, GBIO's ROE is -0.95%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, GBIO is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check LEGN's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, LQDA has a market cap of 3.1B. Regarding current trading prices, GBIO is priced at $5.34, while LQDA trades at $35.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas LQDA's P/E ratio is -43.97. In terms of profitability, GBIO's ROE is -0.95%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, GBIO is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check LQDA's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, DNTH has a market cap of 3.1B. Regarding current trading prices, GBIO is priced at $5.34, while DNTH trades at $79.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas DNTH's P/E ratio is -18.92. In terms of profitability, GBIO's ROE is -0.95%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, GBIO is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check DNTH's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, TLX has a market cap of 3B. Regarding current trading prices, GBIO is priced at $5.34, while TLX trades at $8.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas TLX's P/E ratio is -448.00. In terms of profitability, GBIO's ROE is -0.95%, compared to TLX's ROE of -0.02%. Regarding short-term risk, GBIO is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check TLX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, CPRX has a market cap of 2.9B. Regarding current trading prices, GBIO is priced at $5.34, while CPRX trades at $23.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas CPRX's P/E ratio is 14.15. In terms of profitability, GBIO's ROE is -0.95%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, GBIO is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check CPRX's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, DNLI has a market cap of 2.9B. Regarding current trading prices, GBIO is priced at $5.34, while DNLI trades at $18.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas DNLI's P/E ratio is -6.09. In terms of profitability, GBIO's ROE is -0.95%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, GBIO is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check DNLI's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, GBIO is priced at $5.34, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas MORF's P/E ratio is -14.88. In terms of profitability, GBIO's ROE is -0.95%, compared to MORF's ROE of -0.29%. Regarding short-term risk, GBIO is less volatile compared to MORF. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check MORF's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, GBIO is priced at $5.34, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas MOR's P/E ratio is -12.64. In terms of profitability, GBIO's ROE is -0.95%, compared to MOR's ROE of -1.84%. Regarding short-term risk, GBIO is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check MOR's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, TARS has a market cap of 2.8B. Regarding current trading prices, GBIO is priced at $5.34, while TARS trades at $66.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas TARS's P/E ratio is -42.09. In terms of profitability, GBIO's ROE is -0.95%, compared to TARS's ROE of -0.20%. Regarding short-term risk, GBIO is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check TARS's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, DYN has a market cap of 2.8B. Regarding current trading prices, GBIO is priced at $5.34, while DYN trades at $17.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas DYN's P/E ratio is -4.93. In terms of profitability, GBIO's ROE is -0.95%, compared to DYN's ROE of -0.61%. Regarding short-term risk, GBIO is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check DYN's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, IDYA has a market cap of 2.8B. Regarding current trading prices, GBIO is priced at $5.34, while IDYA trades at $31.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas IDYA's P/E ratio is -24.57. In terms of profitability, GBIO's ROE is -0.95%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, GBIO is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check IDYA's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, SYRE has a market cap of 2.7B. Regarding current trading prices, GBIO is priced at $5.34, while SYRE trades at $45.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas SYRE's P/E ratio is -22.94. In terms of profitability, GBIO's ROE is -0.95%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, GBIO is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check SYRE's competition here

GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GBIO stands at 36M. In comparison, VERA has a market cap of 2.7B. Regarding current trading prices, GBIO is priced at $5.34, while VERA trades at $38.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GBIO currently has a P/E ratio of -0.57, whereas VERA's P/E ratio is -8.18. In terms of profitability, GBIO's ROE is -0.95%, compared to VERA's ROE of -0.60%. Regarding short-term risk, GBIO is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.Check VERA's competition here